Search research articles
Contact Us
Filters
Showing results (41-50 of 106) with videos related to
Page
of 11
Sort By:
Der Urologe. Ausg. A
|
June 2, 2004
[Active studies of prostate carcinoma in 2004]
H Rexer
Der Urologe. Ausg. A
|
August 19, 2004
[First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012]
H Rexer
Der Urologe. Ausg. A
|
March 15, 2005
[The Association of Urological Oncology (AOU) German Cancer Society e.V. The competent counterpart for research in Uro-oncology]
H Rexer,
Der Urologe. Ausg. A
|
October 10, 2014
[Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]]
H Rexer
Der Urologe. Ausg. A
|
February 22, 2014
[First-line therapy for low-risk prostate cancer: prospective phase II study of focal therapy (hemiablation) of the prostate with high intensity focused ultrasound (HIFU) in patients suitable for "Active Surveillance" (AP 68/11 of the AUO)]
H Rexer
Der Urologe. Ausg. A
|
November 3, 2005
[International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer]
Frau H Rexer
Der Urologe. Ausg. A
|
August 19, 2007
[Urologic Oncology Study Society. Promotor and facilitator of uro-oncologic clinical research]
H Rexer, S Krege
Der Urologe. Ausg. A
|
December 22, 2016
[Phase II study with metastatic castration-resistant prostate cancer (mCRPC) patients]
H Rexer, M Graefen
Der Urologe. Ausg. A
|
February 2, 2017
[Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO]
H Rexer, M Graefen
Der Urologe. Ausg. A
|
July 17, 2016
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO]
H Rexer, C Doehn
Page
of 11
Search research articles
Search
Showing results (41-50 of 106) with videos related to
Sort By:
Page
of 11
Der Urologe. Ausg. A
|
June 2, 2004
[Active studies of prostate carcinoma in 2004]
H Rexer
Der Urologe. Ausg. A
|
August 19, 2004
[First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012]
H Rexer
Der Urologe. Ausg. A
|
March 15, 2005
[The Association of Urological Oncology (AOU) German Cancer Society e.V. The competent counterpart for research in Uro-oncology]
H Rexer,
Der Urologe. Ausg. A
|
October 10, 2014
[Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]]
H Rexer
Der Urologe. Ausg. A
|
February 22, 2014
[First-line therapy for low-risk prostate cancer: prospective phase II study of focal therapy (hemiablation) of the prostate with high intensity focused ultrasound (HIFU) in patients suitable for "Active Surveillance" (AP 68/11 of the AUO)]
H Rexer
Der Urologe. Ausg. A
|
November 3, 2005
[International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer]
Frau H Rexer
Der Urologe. Ausg. A
|
August 19, 2007
[Urologic Oncology Study Society. Promotor and facilitator of uro-oncologic clinical research]
H Rexer, S Krege
Der Urologe. Ausg. A
|
December 22, 2016
[Phase II study with metastatic castration-resistant prostate cancer (mCRPC) patients]
H Rexer, M Graefen
Der Urologe. Ausg. A
|
February 2, 2017
[Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO]
H Rexer, M Graefen
Der Urologe. Ausg. A
|
July 17, 2016
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO]
H Rexer, C Doehn
Page
of 11